Summary: The World Economic Forum’s annual meeting in Davos, Switzerland, hosted a session about psychedelics titled, “The New Science of Psychedelics”, where scientist Robin Carhart-Harris spoke about the potential of psychedelics becoming legal treatment options for mental health conditions. Business Insider spoke with Carhart-Harris about his presentation and his observation that non-profits, like MAPS, have paved the way for psychedelic research through fundraising, while currently there is a growing trend in for-profit business models.
Originally appearing here.
First, there were the cancer patients. In a handful of people diagnosed with advanced stages of the disease, a single dose of magic mushrooms appeared to quell their anxiety about death.
Then there were the veterans, whose intrusive flashbacks of violence seemed to be quieted by therapy sessions that involved ecstasy. And recently, a group of people with depression appeared to find some relief in ayahuasca, a hallucinogenic brew that indigenous communities in South America have used for thousands of years.
All that research reached the world stage this week at the World Economic Forum’s annual meeting in Davos, Switzerland. There, a leading British scientist who studies the impact of psychedelics on the brain said things are looking up for psychedelics turning into approved treatments.
“The climate’s looking good,” Robin Carhart-Harris, the head of psychedelic research at the center for neuroscience and pharmacology at London’s Imperial College, said during a Wednesday session at Davos titled “The New Science of Psychedelics.” He spoke in an interview with Alyson Shontell, the editor in chief of Business Insider US.
Research on psychedelics — a word that comes from the Greek roots “psyche,” or soul, and “delos,” or manifest — has been heating up in recent years. The drugs appear to have a unique ability to treat conditions that fail to respond to even the best current treatments. Oftentimes, all that’s required to see those effects is a single dose, or “trip,” in a supervised medical setting.
Nonprofit groups have largely blazed the psychedelic trail for the past few years. The Multidisciplinary Association for Psychedelic Studies, for example, has raised more than $70 million for research on MDMA, marijuana, LSD, and ayahuasca.
But a new crop of interested parties has arrived on the psychedelic scene more recently: for-profit groups.
Last summer, a startup backed by Silicon Valley tech mogul Peter Thiel churned out enough of the active ingredient in magic mushrooms to send 20,000 people on a psychedelic trip — part of a larger research effort by the company, called Compass Pathways, to study how psychedelic drugs could be used to treat depression. Then in November, a German entrepreneur launched a new company called Atai Life Sciences with $25 million to back more studies that explore the therapeutic potential of psychedelic drugs on psychiatric disease.
“The investment is coming in, and that’s interesting that it’s commerce leading the way in terms of being visionary,” Carhart-Harris said.Today, two psychedelic drug candidates are leading the way: psilocybin, the active ingredient in magic mushrooms, and MDMA, also known as ecstasy.
Researchers are particularly interested in how psilocybin appears to quell the symptoms of severe depression — especially versions of the disease that fail to respond to as many as a half-dozen other top-line treatments. Similarly, they’re fascinated by how MDMA — in the context of talk therapy — seems to help treat post-traumatic stress disorder brought on by an acute experience of violence, like in war, or tied to any other cause.
Like any other drug, however, psychedelics can come with side effects that Carhart-Harris said we shouldn’t necessarily ignore.
For example, people who’ve been given psilocybin for anxiety often describe an anxiety-provoking experience during the treatment before they begin to feel the drug’s therapeutic effects.
Also, some people are not good candidates for psychedelic drugs, such as those with a family history of schizophrenia or bipolar disorder, Carhart-Harris added.
If all continues as planned, experts say we should start to see the first legal uses of psychedelics as medicine within the next few years. On Wednesday, Carhart-Harris said he hoped to see something happen along those lines — and likely in severe depression — by 2024.